220 related articles for article (PubMed ID: 35462564)
21. Decreasing disease severity in symptomatic, Smn(-/-);SMN2(+/+), spinal muscular atrophy mice following scAAV9-SMN delivery.
Glascock JJ; Osman EY; Wetz MJ; Krogman MM; Shababi M; Lorson CL
Hum Gene Ther; 2012 Mar; 23(3):330-5. PubMed ID: 22029744
[TBL] [Abstract][Full Text] [Related]
22. Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models.
Kim JK; Jha NN; Feng Z; Faleiro MR; Chiriboga CA; Wei-Lapierre L; Dirksen RT; Ko CP; Monani UR
J Clin Invest; 2020 Mar; 130(3):1271-1287. PubMed ID: 32039917
[TBL] [Abstract][Full Text] [Related]
23. Astrocytes influence the severity of spinal muscular atrophy.
Rindt H; Feng Z; Mazzasette C; Glascock JJ; Valdivia D; Pyles N; Crawford TO; Swoboda KJ; Patitucci TN; Ebert AD; Sumner CJ; Ko CP; Lorson CL
Hum Mol Genet; 2015 Jul; 24(14):4094-102. PubMed ID: 25911676
[TBL] [Abstract][Full Text] [Related]
24. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.
Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH
PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033
[TBL] [Abstract][Full Text] [Related]
25. SMN Blood Levels in a Porcine Model of Spinal Muscular Atrophy.
Iyer CC; Wang X; Renusch SR; Duque SI; Wehr AM; Mo XM; McGovern VL; Arnold WD; Burghes AH; Kolb SJ
J Neuromuscul Dis; 2017; 4(1):59-66. PubMed ID: 28269795
[TBL] [Abstract][Full Text] [Related]
26. Interaction between alpha-COP and SMN ameliorates disease phenotype in a mouse model of spinal muscular atrophy.
Custer SK; Astroski JW; Li HX; Androphy EJ
Biochem Biophys Res Commun; 2019 Jun; 514(2):530-537. PubMed ID: 31060774
[TBL] [Abstract][Full Text] [Related]
27. Decreased Motor Neuron Support by SMA Astrocytes due to Diminished MCP1 Secretion.
Martin JE; Nguyen TT; Grunseich C; Nofziger JH; Lee PR; Fields D; Fischbeck KH; Foran E
J Neurosci; 2017 May; 37(21):5309-5318. PubMed ID: 28450545
[TBL] [Abstract][Full Text] [Related]
28. Moving towards treatments for spinal muscular atrophy: hopes and limits.
Wirth B; Barkats M; Martinat C; Sendtner M; Gillingwater TH
Expert Opin Emerg Drugs; 2015 Sep; 20(3):353-6. PubMed ID: 25920617
[TBL] [Abstract][Full Text] [Related]
29. Motor transmission defects with sex differences in a new mouse model of mild spinal muscular atrophy.
Deguise MO; De Repentigny Y; Tierney A; Beauvais A; Michaud J; Chehade L; Thabet M; Paul B; Reilly A; Gagnon S; Renaud JM; Kothary R
EBioMedicine; 2020 May; 55():102750. PubMed ID: 32339936
[TBL] [Abstract][Full Text] [Related]
30. Motor unit recovery following Smn restoration in mouse models of spinal muscular atrophy.
Comley LH; Kline RA; Thomson AK; Woschitz V; Landeros EV; Osman EY; Lorson CL; Murray LM
Hum Mol Genet; 2022 Sep; 31(18):3107-3119. PubMed ID: 35551393
[TBL] [Abstract][Full Text] [Related]
31. PTEN depletion decreases disease severity and modestly prolongs survival in a mouse model of spinal muscular atrophy.
Little D; Valori CF; Mutsaers CA; Bennett EJ; Wyles M; Sharrack B; Shaw PJ; Gillingwater TH; Azzouz M; Ning K
Mol Ther; 2015 Feb; 23(2):270-7. PubMed ID: 25369768
[TBL] [Abstract][Full Text] [Related]
32. AAV9-mediated SMN gene therapy rescues cardiac desmin but not lamin A/C and elastin dysregulation in Smn2B/- spinal muscular atrophy mice.
Brown SJ; Šoltić D; Synowsky SA; Shirran SL; Chilcott E; Shorrock HK; Gillingwater TH; Yáñez-Muñoz RJ; Schneider B; Bowerman M; Fuller HR
Hum Mol Genet; 2023 Oct; 32(20):2950-2965. PubMed ID: 37498175
[TBL] [Abstract][Full Text] [Related]
33. A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology.
Bowerman M; Murray LM; Beauvais A; Pinheiro B; Kothary R
Neuromuscul Disord; 2012 Mar; 22(3):263-76. PubMed ID: 22071333
[TBL] [Abstract][Full Text] [Related]
34. Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset.
Feng Z; Ling KK; Zhao X; Zhou C; Karp G; Welch EM; Naryshkin N; Ratni H; Chen KS; Metzger F; Paushkin S; Weetall M; Ko CP
Hum Mol Genet; 2016 Mar; 25(5):964-75. PubMed ID: 26758873
[TBL] [Abstract][Full Text] [Related]
35. Fetal Gene Therapy Using a Single Injection of Recombinant AAV9 Rescued SMA Phenotype in Mice.
Rashnonejad A; Amini Chermahini G; Gündüz C; Onay H; Aykut A; Durmaz B; Baka M; Su Q; Gao G; Özkınay F
Mol Ther; 2019 Dec; 27(12):2123-2133. PubMed ID: 31543414
[TBL] [Abstract][Full Text] [Related]
36. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.
Williams JH; Schray RC; Patterson CA; Ayitey SO; Tallent MK; Lutz GJ
J Neurosci; 2009 Jun; 29(24):7633-8. PubMed ID: 19535574
[TBL] [Abstract][Full Text] [Related]
37. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
Wood MJA; Talbot K; Bowerman M
Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
[TBL] [Abstract][Full Text] [Related]
38. AAV9-DOK7 gene therapy reduces disease severity in Smn
Kaifer KA; Villalón E; Smith CE; Simon ME; Marquez J; Hopkins AE; Morcos TI; Lorson CL
Biochem Biophys Res Commun; 2020 Sep; 530(1):107-114. PubMed ID: 32828271
[TBL] [Abstract][Full Text] [Related]
39. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
[TBL] [Abstract][Full Text] [Related]
40. Proteomic assessment of a cell model of spinal muscular atrophy.
Wu CY; Whye D; Glazewski L; Choe L; Kerr D; Lee KH; Mason RW; Wang W
BMC Neurosci; 2011 Mar; 12():25. PubMed ID: 21385431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
